Computing and Information Systems - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 8 of 8
  • Item
    Thumbnail Image
    Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation
    Bandala-Sanchez, E ; Roth-Schulze, AJ ; Oakey, H ; Penno, MAS ; Bediaga, NG ; Naselli, G ; Ngui, KM ; Smith, AD ; Huang, D ; Zozaya-Valdes, E ; Thomson, RL ; Brown, JD ; Vuillermin, PJ ; Barry, SC ; Craig, ME ; Rawlinson, WD ; Davis, EA ; Harris, M ; Soldatos, G ; Colman, PG ; Wentworth, JM ; Haynes, A ; Morahan, G ; Sinnott, RO ; Papenfuss, AT ; Couper, JJ ; Harrison, LC (ELSEVIER IRELAND LTD, 2022-02)
    AIMS: Studies of the gut microbiome have focused on its bacterial composition. We aimed to characterize the gut fungal microbiome (mycobiome) across pregnancy in women with and without type 1 diabetes. METHODS: Faecal samples (n = 162) were collected from 70 pregnant women (45 with and 25 without type 1 diabetes) across all trimesters. Fungi were analysed by internal transcribed spacer 1 amplicon sequencing. Markers of intestinal inflammation (faecal calprotectin) and intestinal epithelial integrity (serum intestinal fatty acid binding protein; I-FABP), and serum antibodies to Saccharomyces cerevisiae (ASCA) were measured. RESULTS: Women with type 1 diabetes had decreased fungal alpha diversity by the third trimester, associated with an increased abundance of Saccharomyces cerevisiae that was inversely related to the abundance of the anti-inflammatory butyrate-producing bacterium Faecalibacterium prausnitzii. Women with type 1 diabetes had higher concentrations of calprotectin, I-FABP and ASCA. CONCLUSIONS: Women with type 1 diabetes exhibit a shift in the gut mycobiome across pregnancy associated with evidence of gut inflammation and impaired intestinal barrier function. The relevance of these findings to the higher rate of pregnancy complications in type 1 diabetes warrants further study.
  • Item
    No Preview Available
    Evaluation of protocol amendments to the Environmental Determinants of Islet Autoimmunity (ENDIA) study during the COVID-19 pandemic
    Penno, MAS ; Anderson, AJ ; Thomson, RL ; McGorm, K ; Barry, SC ; Colman, PG ; Craig, ME ; Davis, EA ; Harris, M ; Haynes, A ; Morahan, G ; Oakey, H ; Rawlinson, WD ; Sinnott, RO ; Soldatos, G ; Vuillermin, PJ ; Wentworth, JM ; Harrison, LC ; Couper, JJ (WILEY, 2021-11)
  • Item
    Thumbnail Image
    Type 1 diabetes in pregnancy is associated with distinct changes in the composition and function of the gut microbiome
    Roth-Schulze, AJ ; Penno, MAS ; Ngui, KM ; Oakey, H ; Bandala-Sanchez, E ; Smith, AD ; Allnutt, TR ; Thomson, RL ; Vuillermin, PJ ; Craig, ME ; Rawlinson, WD ; Davis, EA ; Harris, M ; Soldatos, G ; Colman, PG ; Wentworth, JM ; Haynes, A ; Barry, SC ; Sinnott, RO ; Morahan, G ; Bediaga, NG ; Smyth, GK ; Papenfuss, AT ; Couper, JJ ; Harrison, LC (BMC, 2021-08-06)
    BACKGROUND: The gut microbiome changes in response to a range of environmental conditions, life events and disease states. Pregnancy is a natural life event that involves major physiological adaptation yet studies of the microbiome in pregnancy are limited and their findings inconsistent. Pregnancy with type 1 diabetes (T1D) is associated with increased maternal and fetal risks but the gut microbiome in this context has not been characterized. By whole metagenome sequencing (WMS), we defined the taxonomic composition and function of the gut bacterial microbiome across 70 pregnancies, 36 in women with T1D. RESULTS: Women with and without T1D exhibited compositional and functional changes in the gut microbiome across pregnancy. Profiles in women with T1D were distinct, with an increase in bacteria that produce lipopolysaccharides and a decrease in those that produce short-chain fatty acids, especially in the third trimester. In addition, women with T1D had elevated concentrations of fecal calprotectin, a marker of intestinal inflammation, and serum intestinal fatty acid-binding protein (I-FABP), a marker of intestinal epithelial damage. CONCLUSIONS: Women with T1D exhibit a shift towards a more pro-inflammatory gut microbiome during pregnancy, associated with evidence of intestinal inflammation. These changes could contribute to the increased risk of pregnancy complications in women with T1D and are potentially modifiable by dietary means. Video abstract.
  • Item
    Thumbnail Image
    Higher frequency of vertebrate-infecting viruses in the gut of infants born to mothers with type 1 diabetes
    Kim, KW ; Allen, DW ; Briese, T ; Couper, JJ ; Barry, SC ; Colman, PG ; Cotterill, AM ; Davis, EA ; Giles, LC ; Harrison, LC ; Harris, M ; Haynes, A ; Horton, JL ; Isaacs, SR ; Jain, K ; Lipkin, WI ; McGorm, K ; Morahan, G ; Morbey, C ; Pang, ICN ; Papenfuss, AT ; Penno, MAS ; Sinnott, RO ; Soldatos, G ; Thomson, RL ; Vuillermin, P ; Wentworth, JM ; Wilkins, MR ; Rawlinson, WD ; Craig, ME (WILEY, 2020-02-05)
    Background: Microbial exposures in utero and early life shape the infant microbiome, which can profoundly impact on health. Compared to the bacterial microbiome, very little is known about the virome. We set out to characterize longitudinal changes in the gut virome of healthy infants born to mothers with or without type 1 diabetes using comprehensive virome capture sequencing. Methods: Healthy infants were selected from Environmental Determinants of Islet Autoimmunity (ENDIA), a prospective cohort of Australian children with a first‐degree relative with type 1 diabetes, followed from pregnancy. Fecal specimens were collected three‐monthly in the first year of life. Results: Among 25 infants (44% born to mothers with type 1 diabetes) at least one virus was detected in 65% (65/100) of samples and 96% (24/25) of infants during the first year of life. In total, 26 genera of viruses were identified and >150 viruses were differentially abundant between the gut of infants with a mother with type 1 diabetes vs without. Positivity for any virus was associated with maternal type 1 diabetes and older infant age. Enterovirus was associated with older infant age and maternal smoking. Conclusions: We demonstrate a distinct gut virome profile in infants of mothers with type 1 diabetes, which may influence health outcomes later in life. Higher prevalence and greater number of viruses observed compared to previous studies suggests significant underrepresentation in existing virome datasets, arising most likely from less sensitive techniques used in data acquisition.
  • Item
    Thumbnail Image
    Changes in pancreatic exocrine function in young at-risk children followed to islet autoimmunity and type 1 diabetes in the ENDIA study
    Penno, MAS ; Oakey, H ; Augustine, P ; Taranto, M ; Barry, SC ; Colman, PG ; Craig, ME ; Davis, EA ; Giles, LC ; Harris, M ; Haynes, A ; McGorm, K ; Morahan, G ; Morbey, C ; Rawlinson, WD ; Sinnott, RO ; Soldatos, G ; Thomson, RL ; Vuillermin, PJ ; Wentworth, JM ; Harrison, LC ; Couper, JJ (WILEY, 2020-09)
    BACKGROUNDS: We aimed to monitor pancreatic exocrine function longitudinally in relation to the development of islet autoimmunity (IA) and type 1 diabetes (T1D) in at-risk children with a first-degree relative with T1D, who were followed prospectively in the Environmental Determinants of Islet Autoimmunity (ENDIA) study. METHODS: Fecal elastase-1 (FE-1) concentration was measured longitudinally in 85 ENDIA children from median age 1.0 (IQR 0.7,1.3) year. Twenty-eight of 85 children (progressors) developed persistent islet autoantibodies at median age of 1.5 (IQR 1.1,2.5) years, of whom 11 went on to develop clinical diabetes. The other 57 islet autoantibody-negative children (non-progressors) followed similarly were age and gender-matched with the progressors. An adjusted linear mixed model compared FE-1 concentrations in progressors and non-progressors. RESULTS: Baseline FE-1 did not differ between progressors and non-progressors, or by HLA DR type or proband status. FE-1 decreased over time in progressors in comparison to non-progressors (Wald statistic 5.46, P = .02); in some progressors the fall in FE-1 preceded the onset of IA. CONCLUSIONS: Pancreatic exocrine function decreases in the majority of young at-risk children who progress to IA and T1D.
  • Item
    Thumbnail Image
    Influence of fecal collection conditions and 16S rRNA gene sequencing at two centers on human gut microbiota analysis
    Penington, JS ; Penno, MAS ; Ngui, KM ; Ajami, NJ ; Roth-Schulze, AJ ; Wilcox, SA ; Bandala-Sanchez, E ; Wentworth, JM ; Barry, SC ; Brown, CY ; Couper, JJ ; Petrosino, JF ; Papenfuss, AT ; Harrison, LC (NATURE PORTFOLIO, 2018-03-12)
    To optimise fecal sampling for reproducible analysis of the gut microbiome, we compared different methods of sample collection and sequencing of 16S rRNA genes at two centers. Samples collected from six individuals on three consecutive days were placed in commercial collection tubes (OMNIgeneGut OMR-200) or in sterile screw-top tubes in a home fridge or home freezer for 6-24 h, before transfer and storage at -80 °C. Replicate samples were shipped to centers in Australia and the USA for DNA extraction and sequencing by their respective PCR protocols, and analysed with the same bioinformatic pipeline. Variation in gut microbiome was dominated by differences between individuals. Minor differences in the abundance of taxa were found between collection-processing methods and day of collection, and between the two centers. We conclude that collection with storage and transport at 4 °C within 24 h is adequate for 16S rRNA analysis of the gut microbiome. Other factors including differences in PCR and sequencing methods account for relatively minor variation compared to differences between individuals.
  • Item
    Thumbnail Image
    Distinct Gut Virome Profile of Pregnant Women With Type 1 Diabetes in the ENDIA Study
    Kim, KW ; Allen, DW ; Briese, T ; Couper, JJ ; Barry, SC ; Colman, PG ; Cotterill, AM ; Davis, EA ; Giles, LC ; Harrison, LC ; Harris, M ; Haynes, A ; Horton, JL ; Isaacs, SR ; Jain, K ; Lipkin, WI ; Morahan, G ; Morbey, C ; Pang, ICN ; Papenfuss, AT ; Penno, MAS ; Sinnott, RO ; Soldatos, G ; Thomson, RL ; Vuillermin, PJ ; Wentworth, JM ; Wilkins, MR ; Rawlinson, WD ; Craig, ME (OXFORD UNIV PRESS INC, 2019-02)
    BACKGROUND: The importance of gut bacteria in human physiology, immune regulation, and disease pathogenesis is well established. In contrast, the composition and dynamics of the gut virome are largely unknown; particularly lacking are studies in pregnancy. We used comprehensive virome capture sequencing to characterize the gut virome of pregnant women with and without type 1 diabetes (T1D), longitudinally followed in the Environmental Determinants of Islet Autoimmunity study. METHODS: In total, 61 pregnant women (35 with T1D and 26 without) from Australia were examined. Nucleic acid was extracted from serial fecal specimens obtained at prenatal visits, and viral genomes were sequenced by virome capture enrichment. The frequency, richness, and abundance of viruses were compared between women with and without T1D. RESULTS: Two viruses were more prevalent in pregnant women with T1D: picobirnaviruses (odds ratio [OR], 4.2; 95% confidence interval [CI], 1.0-17.1; P = .046) and tobamoviruses (OR, 3.2; 95% CI, 1.1-9.3; P = .037). The abundance of 77 viruses significantly differed between the 2 maternal groups (≥2-fold difference; P < .02), including 8 Enterovirus B types present at a higher abundance in women with T1D. CONCLUSIONS: These findings provide novel insight into the composition of the gut virome during pregnancy and demonstrate a distinct profile of viruses in women with T1D.
  • Item
    Thumbnail Image
    Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes
    Penno, MAS ; Couper, JJ ; Craig, ME ; Colman, PG ; Rawlinson, WD ; Cotterill, AM ; Jones, TW ; Harrison, LC (BMC, 2013-08-14)
    BACKGROUND: The incidence of type 1 diabetes has increased worldwide, particularly in younger children and those with lower genetic susceptibility. These observations suggest factors in the modern environment promote pancreatic islet autoimmunity and destruction of insulin-producing beta cells. The Environmental Determinants of Islet Autoimmunity (ENDIA) Study is investigating candidate environmental exposures and gene-environment interactions that may contribute to the development of islet autoimmunity and type 1 diabetes. METHODS/DESIGN: ENDIA is the only prospective pregnancy/birth cohort study in the Southern Hemisphere investigating the determinants of type 1 diabetes in at-risk children. The study will recruit 1,400 unborn infants or infants less than six months of age with a first-degree relative (i.e. mother, father or sibling) with type 1 diabetes, across five Australian states. Pregnant mothers/infants will be followed prospectively from early pregnancy through childhood to investigate relationships between genotype, the development of islet autoimmunity (and subsequently type 1 diabetes), and prenatal and postnatal environmental factors. ENDIA will evaluate the microbiome, nutrition, bodyweight/composition, metabolome-lipidome, insulin resistance, innate and adaptive immune function and viral infections. A systems biology approach will be used to integrate these data. Investigation will be by 3-monthly assessments of the mother during pregnancy, then 3-monthly assessments of the child until 24 months of age and 6-monthly thereafter. The primary outcome measure is persistent islet autoimmunity, defined as the presence of autoantibodies to one or more islet autoantigens on consecutive tests. DISCUSSION: Defining gene-environment interactions that initiate and/or promote destruction of the insulin-producing beta cells in early life will inform approaches to primary prevention of type 1 diabetes. The strength of ENDIA is the prospective, comprehensive and frequent systems-wide profiling from early pregnancy through to early childhood, to capture dynamic environmental exposures that may shape the development of islet autoimmunity. TRIAL REGISTRATION: Australia New Zealand Clinical Trials Registry ACTRN12613000794707.